Back to Journals » Vascular Health and Risk Management » Volume 8

Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases

Authors Shinkai H

Received 12 March 2012

Accepted for publication 12 April 2012

Published 15 May 2012 Volume 2012:8 Pages 323—331

DOI https://doi.org/10.2147/VHRM.S25238

Review by Single-blind

Peer reviewer comments 2

Hisashi Shinkai

Central Pharmaceutical Research Institute, JT Inc, Osaka, Japan

Abstract: Elevated low-density lipoprotein (LDL) cholesterol and lowered high-density lipoprotein (HDL) cholesterol are important risk factors for cardiovascular disease. Accordingly, raising HDL cholesterol induced by cholesteryl ester transfer protein (CETP) inhibition is an attractive approach for reducing the residual risk of cardiovascular events that persist in many patients receiving low-density LDL cholesterol-lowering therapy with statins. The development of torcetrapib, a CETP inhibitor, was terminated due to its adverse cardiovascular effects. These adverse effects did not influence the mechanism of CETP inhibition, but affected the molecule itself. Therefore a CETP modulator, dalcetrapib, and a CETP inhibitor, anacetrapib, are in Phase III of clinical trials to evaluate their effects on cardiovascular outcomes. In the dal-VESSEL (dalcetrapib Phase IIb endothelial function study) and the dal-PLAQUE (safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging) clinical studies, dalcetrapib reduced CETP activity by 50% and increased HDL cholesterol levels by 31% without changing LDL cholesterol levels. Moreover, dalcetrapib was associated with a reduction in carotid vessel-wall inflammation at 6 months, as well as a reduced vessel-wall area at 24 months compared with the placebo. In the DEFINE (determining the efficacy and tolerability of CETP inhibition with anacetrapib) clinical study, anacetrapib increased HDL cholesterol levels by 138% and decreased LDL cholesterol levels by 36%. In contrast with torcetrapib, anacetrapib had no adverse cardiovascular effects. The potential of dalcetrapib and anacetrapib in the treatment of cardiovascular diseases will be revealed by two large-scale clinical trials, the dal-OUTCOMES (efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome) study and the REVEAL (randomized evaluation of the effects of anacetrapib through lipid modification, a large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease) study. The dal-OUTCOMES study is testing whether dalcetrapib can reduce cardiovascular events and the REVEAL study is testing whether anacetrapib can reduce cardiovascular events. These reports are expected to be released by 2013 and 2017, respectively.

Keywords: dalcetrapib, anacetrapib, cholesteryl ester transfer protein (CETP), CETP inhibitor, CETP modulator, high-density lipoprotein, cardiovascular disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

The clinical application of linagliptin in Asians

Cao CQ, Xiang YF, Zhou ZG

Therapeutics and Clinical Risk Management 2015, 11:1409-1419

Published Date: 16 September 2015

Toward a patient-based paradigm for blood transfusion

Farrugia A, Vamvakas E

Journal of Blood Medicine 2014, 5:5-13

Published Date: 31 January 2014

Challenges for heart disease stem cell therapy

Hoover-Plow J, Gong Y

Vascular Health and Risk Management 2012, 8:99-113

Published Date: 17 February 2012

Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors

Ampaiwan Chuansumrit, Pantep Angchaisuksiri, Nongnuch Sirachainan

Journal of Blood Medicine 2010, 1:37-48

Published Date: 30 March 2010

Does plasmin have anticoagulant activity?

Jane Hoover-Plow

Vascular Health and Risk Management 2010, 6:199-205

Published Date: 26 March 2010